Oncology Related Products

2-deoxy D-Glucose

Detailed molecular biology and cellular studies on radio-modifying action of the molecule were instrumental in realising its therapeutic potential for enhancing the effect of radiotherapy and making it effective in cancers having poor response to radiotherapy. Examples of such cancers include brain tumour and sarcomas. As this is a frequent clinical problem, the effect of 2-DG on non-surgical treatment of cancers is increasingly being realised and is expected to be very significant. The technology has been transferred to Dr Reddy’s Laboratory after regulatory approvals and successful completion of the initial clinical trials to fulfill the Societal Mission of DRDO.
A formulation developed by DRDO, containing 2-DG and 6-AN in a fixed proportion, is a new development in the area. The formulation is likely to enhance the efficacy of chemotherapy-radiotherapy regimes for cancer cure while reducing the adverse effects substantially.

Cancer Targeting & Diagnostics


                                                                                   ANT               POST                    ANT                       POST


                                                                    1h 99mTc-CDTMP scan               3h 99mTc-MDP scan           1h 99mTc-CDTMP scan.


A number of new radio-pharmaceuticals have been developed specifically for targeting cancerous lesions. The new radiopharmaceuticals have the twin potential for imaging or therapy of the cancerous lesions using conventional nuclear medicine radionuclides. The radiopharmaceuticals targeting primary lesions are usually based on antibodies for receptors, while those targeting bone secondary are phosphonate derivatives with affinity towards abnormal bone. Some of the antibody-based radiopharmaceuticals developed by DRDO are anti-EGFR antibody chelated to DOTA-Ph-Al derivative that acts as a bi-functional chelate, and radiopharmaceutical Tc-99m CDTMP for targeting the abnormal bone.
Other novel cancer targeting radiopharmaceuticals developed by DRDO include Tc-99m methotrexate, Tc-99m folate derivative and a cholecystokinin receptor-based tracer derived from a herbal source. Notable nuclear medicine techniques developed for improved cancer detection include 3/24 h dexamethasone interventional and frusemide interventional bone scan.